ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 39, Issue 10, 2012, Pages 2032-2040

  De Rotte, Maurits C F J ^a   Bulatovic, Maja ^b   Heijstek, Marloes W ^b   Jansen, Gerrit ^c   Heil, Sandra G ^a   Van Schaik, Ron H N ^a   Wulffraat, Nico M ^b   De Jonge, Robert ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gene polymorphisms; Juvenile idiopathic arthritis; Methotrexate

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; BREAST CANCER RESISTANCE PROTEIN; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; GAMMA GLUTAMYL HYDROLASE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER B1 GENE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER C1 GENE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER C2 GENE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER C3 GENE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER C4 GENE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER C5 GENE; ADENOSINE TRIPHOSPHATE BINDING CASSETTE TRANSPORTER G2 GENE; ADULT; ARTICLE; CHILD; DISEASE ACTIVITY; DISEASE CARRIER; DISEASE DURATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TRANSPORT; FEMALE; FOLATE RECEPTOR 1 GENE; FOLATE RECEPTOR 2 GENE; GAMMA GLUTAMYL HYDROLASE GENE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOLUTE CARRIER 19A1 GENE; SOLUTE CARRIER 46A1 GENE; TREATMENT DURATION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; HUMANS; INFANT; MALE; METHOTREXATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 84867223825     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.111593     Document Type: Article

References (54)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201. (Pubitemid 38924397)
3. van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G. Drug insight: Resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat Clin Pract Rheumatol 2007;3:26-34.
4. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006;9:227-46. (Pubitemid 44750843)
5. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: Results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5. (Pubitemid 41113353)
6. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54:3095-103. (Pubitemid 44622078)
7. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20. (Pubitemid 29265678)
8. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74. (Pubitemid 39209513)
9. Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004;14:733-9. (Pubitemid 39552788)
10. Davila L, Ranganathan P. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol 2011;7:537-50.
11. Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol 2005;32:1832-6. (Pubitemid 41324827)
12. Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:46-51.
13. Hinks A, Moncrieffe H, Martin P, Ursu S, Lal S, Kassoumeri L, et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis 2011;70:1395-400.
14. Yanagimachi M, Naruto T, Hara T, Kikuchi M, Hara R, Miyamae T, et al. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J Clin Pharmacol 2011;71:237-43.
15. Becker ML, Gaedigk R, van Haandel L, Thomas B, Lasky A, Hoeltzel M, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011;63:276-85.
16. Tukova J, Chladek J, Hroch M, Nemcova D, Hoza J, Dolezalova P. 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: Treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J Rheumatol 2010;37:2180-6.
17. Moncrieffe H, Hinks A, Ursu S, Kassoumeri L, Etheridge A, Hubank M, et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: Correlation between gene expression and genotype. Pharmacogenet Genomics 2010;20:665-76.
18. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
19. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
20. International Hapmap Project. [Internet. Accessed June 7, 2012.] Available from: http://hapmap.ncbi.nlm.nih.gov/index.html.en
21. National Center for Biotechnology Information. dbSNP short genetic variations. [Internet. Accessed June 7, 2012.] Available from: http://www.ncbi.nlm.nih.gov/projects/SNP/
22. Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008;35:572-9. (Pubitemid 351500051)
23. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008;9:439-51. (Pubitemid 351803927)
24. Gervasini G. Polymorphisms in methotrexate pathways: What is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009;10:547-66.
25. Gradhand U, Tegude H, Burk O, Eichelbaum M, Fromm MF, Konig J. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci 2007;80:1490-4. (Pubitemid 46399747)
26. Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, Moghrabi A, et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 2009;114:1383-6.
27. Ostergaard M, Ernst A, Labouriau R, Dagiliene E, Krarup HB, Christensen M, et al. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand J Gastroenterol 2009;44:65-73.
28. Boyles AL, Wilcox AJ, Taylor JA, Shi M, Weinberg CR, Meyer K, et al. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: A pathway-wide association study. Genet Epidemiol 2009;33:247-55.
29. DeVos L, Chanson A, Liu Z, Ciappio ED, Parnell LD, Mason JB, et al. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am J Clin Nutr 2008;88:1149-58.
30. de Jonge R, Tissing WJ, Hooijberg JH, Jansen G, Kaspers GJ, Lindemans J, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 2009;113:2284-9.
31. Barrett JC, Cardon LR. Evaluating coverage of genome-wide association studies. Nat Genet 2006;38:659-62. (Pubitemid 43927307)
32. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89. (Pubitemid 32289743)
33. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer-Verlag; 2000.
34. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003;88:197-200. (Pubitemid 36269497)
35. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004;42:496-503. (Pubitemid 39255621)
36. Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 2006;62:933-7. (Pubitemid 44657627)
37. Takatori R, Takahashi KA, Tokunaga D, Hojo T, Fujioka M, Asano T, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006;24:546-54. (Pubitemid 44911249)
38. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: A study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 2008;64:1057-68.
39. Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics 2008;18:1041-9.
40. Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010;11:163-75.
41. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8. (Pubitemid 30183327)
42. de Graaf D, Sharma RC, Mechetner EB, Schimke RT, Roninson IB. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 1996;93:1238-42. (Pubitemid 26052872)
43. Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J, et al. Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer 1996;65:613-9. (Pubitemid 26092290)
44. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit-Singh CS. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci 2004;93:957-68. (Pubitemid 38420406)
45. Hider SL, Hoggard P, Khoo S, Back D, Bruce IN. Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer. Arthritis Rheum 2005;52:670; author reply 2.
46. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-8. (Pubitemid 24135836)
47. van de Ven R, Oerlemans R, van der Heijden JW, Scheffer GL, de Gruijl TD, Jansen G, et al. ABC drug transporters and immunity: Novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 2009;86:1075-87.
48. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-9. (Pubitemid 29274984)
49. Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, et al. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004;14:155-64. (Pubitemid 38373109)
50. Doerfel C, Rump A, Sauerbrey A, Gruhn B, Zintl F, Steinbach D. In acute leukemia, the polymorphism -211C>T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene. Pharmacogenet Genomics 2006;16:149-50. (Pubitemid 43145683)
51. Nemes S, Jonasson JM, Genell A, Steineck G. Bias in odds ratios by logistic regression modelling and sample size. BMC Med Res Methodol 2009;9:56.
52. Mowinckel P, Hagen KB, Heiberg T, Kvien TK. Repeated measures in rheumatoid arthritis reduced the required sample size in a two-armed clinical trial. J Clin Epidemiol 2008;61:940-4.
53. de Rotte MC, Luime JJ, Bulatovic M, Hazes JM, Wulffraat NM, de Jonge R. Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research? Rheumatology 2010;49:1200-1.
54. Dervieux T, Wessels JA, Kremer JM, Padyukov L, Seddighzadeh M, Saevarsdottir S, et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics 2012;22:1-9.